MedTrace Logo

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

NCT00794131 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-04-24

No results posted yet for this study

Summary

The main purpose of this study is to determine whether, GL-ONC1, an Oncolytic Virus, can safely be administered intravenously in patients with advanced solid tumors.

Conditions

  • Advanced Cancers (Solid Tumors)

Interventions

BIOLOGICAL

GL-ONC1

a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )

Sponsors & Collaborators

  • Genelux GmbH

    lead INDUSTRY

Principal Investigators

  • Johann de Bono, MD FRCP MSc PhD · Royal Marsdon Hospital/Institute for Cancer Research

  • Kevin Harrington, MBBS MRCP FRCR · Royal Marsden Hospital/Institute of Cancer Research

  • Hardev Pandha, MD,FRCP,FRACP,PhD · Surrey Clinical Research Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United Kingdom

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00794131 on ClinicalTrials.gov